157 related articles for article (PubMed ID: 22061823)
1. Capturing of the free cysteine residue in the ligand-binding site by affinity labeling of the ORL1 nociceptin receptor.
Matsushima A; Nishimura H; Inamine S; Uemura S; Shimohigashi Y
Bioorg Med Chem; 2011 Dec; 19(24):7597-602. PubMed ID: 22061823
[TBL] [Abstract][Full Text] [Related]
2. Specific affinity-labeling of the nociceptin ORL1 receptor using a thiol-activated Cys(Npys)-containing peptide ligand.
Matsushima A; Nishimura H; Matsuyama Y; Liu X; Costa T; Shimohigashi Y
Biopolymers; 2016 Nov; 106(4):460-9. PubMed ID: 27271345
[TBL] [Abstract][Full Text] [Related]
3. Tritium-labelled isovaleryl-RYYRIK-NH2 as potential antagonist probe for ORL1 nociceptin receptor.
Inamine S; Nishimura H; Li J; Isozaki K; Matsushima A; Costa T; Shimohigashi Y
Bioorg Med Chem; 2014 Nov; 22(21):5902-9. PubMed ID: 25284251
[TBL] [Abstract][Full Text] [Related]
4. Opioid receptor-like 1 (ORL1) receptor binding and the biological properties of Ac-Arg-Tyr-Tyr-Arg-Ile-Arg-NH2 and its analogs.
Ambo A; Kohara H; Kawano S; Sasaki Y
J Pept Sci; 2007 Oct; 13(10):672-8. PubMed ID: 17712865
[TBL] [Abstract][Full Text] [Related]
5. Exploration of universal cysteines in the binding sites of three opioid receptor subtypes by disulfide-bonding affinity labeling with chemically activated thiol-containing dynorphin A analogs.
Shirasu N; Kuromizu T; Nakao H; Chuman Y; Nose T; Costa T; Shimohigashi Y
J Biochem; 1999 Jul; 126(1):254-9. PubMed ID: 10393346
[TBL] [Abstract][Full Text] [Related]
6. Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin.
Moulédous L; Topham CM; Mazarguil H; Meunier JC
J Biol Chem; 2000 Sep; 275(38):29268-74. PubMed ID: 10880520
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding.
Kawano C; Okada K; Honda T; Nose T; Sakaguchi K; Costa T; Shimohigashi Y
J Pept Sci; 2002 Oct; 8(10):561-9. PubMed ID: 12450325
[TBL] [Abstract][Full Text] [Related]
8. Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
Bioorg Med Chem; 2008 Mar; 16(5):2635-44. PubMed ID: 18068993
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
10. Identification of a hexapeptide binding region in the nociceptin (ORL1) receptor by photo-affinity labelling with Ac-Arg-Bpa-Tyr-Arg-Trp-Arg-NH2.
Bes B; Meunier JC
Biochem Biophys Res Commun; 2003 Oct; 310(3):992-1001. PubMed ID: 14550303
[TBL] [Abstract][Full Text] [Related]
11. N-methylthioacetylation of RYYRIK-NH2 with enhanced specific binding affinity and high antagonist activity for nociceptin ORL1 receptor.
Li J; Nishimura H; Matsushima A; Shimohigashi Y
Bioorg Med Chem; 2014 Nov; 22(21):5721-6. PubMed ID: 25319085
[TBL] [Abstract][Full Text] [Related]
12. Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a micro-opioid receptor agonist and an ORL1 receptor antagonist.
Kawano S; Ito R; Nishiyama M; Kubo M; Matsushima T; Minamisawa M; Ambo A; Sasaki Y
Biol Pharm Bull; 2007 Jul; 30(7):1260-4. PubMed ID: 17603164
[TBL] [Abstract][Full Text] [Related]
13. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Kawano S; Ambo A; Sasaki Y
Bioorg Med Chem Lett; 2006 Sep; 16(18):4839-41. PubMed ID: 16814543
[TBL] [Abstract][Full Text] [Related]
15. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
[TBL] [Abstract][Full Text] [Related]
16. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids.
Mollereau C; Moisand C; Butour JL; Parmentier M; Meunier JC
FEBS Lett; 1996 Oct; 395(1):17-21. PubMed ID: 8849681
[TBL] [Abstract][Full Text] [Related]
17. Different domains of the ORL1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A.
Lapalu S; Moisand C; Butour JL; Mollereau C; Meunier JC
FEBS Lett; 1998 May; 427(2):296-300. PubMed ID: 9607332
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide.
Shimohigashi Y; Hatano R; Fujita T; Nakashima R; Nose T; Sujaku T; Saigo A; Shinjo K; Nagahisa A
J Biol Chem; 1996 Sep; 271(39):23642-5. PubMed ID: 8798582
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
[TBL] [Abstract][Full Text] [Related]
20. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol.
Bojnik E; Farkas J; Magyar A; Tömböly C; Güçlü U; Gündüz O; Borsodi A; Corbani M; Benyhe S
Neurochem Int; 2009 Dec; 55(7):458-66. PubMed ID: 19414055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
